308 related articles for article (PubMed ID: 32829467)
1. Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome.
Bouadma L; Wiedemann A; Patrier J; Surénaud M; Wicky PH; Foucat E; Diehl JL; Hejblum BP; Sinnah F; de Montmollin E; Lacabaratz C; Thiébaut R; Timsit JF; Lévy Y
J Clin Immunol; 2020 Nov; 40(8):1082-1092. PubMed ID: 32829467
[TBL] [Abstract][Full Text] [Related]
2. Severe COVID-19: what have we learned with the immunopathogenesis?
Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.
Napp LC; Bauersachs J
Shock; 2020 Nov; 54(5):700-701. PubMed ID: 32453251
[No Abstract] [Full Text] [Related]
4. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.
Weiskopf D; Schmitz KS; Raadsen MP; Grifoni A; Okba NMA; Endeman H; van den Akker JPC; Molenkamp R; Koopmans MPG; van Gorp ECM; Haagmans BL; de Swart RL; Sette A; de Vries RD
Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32591408
[TBL] [Abstract][Full Text] [Related]
5. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
[No Abstract] [Full Text] [Related]
6. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
Bishop MR
Clin Adv Hematol Oncol; 2020 Jul; 18(7):400-403. PubMed ID: 32903251
[No Abstract] [Full Text] [Related]
7. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
8. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors.
Mustafa MI; Abdelmoneim AH; Mahmoud EM; Makhawi AM
Mediators Inflamm; 2020; 2020():8198963. PubMed ID: 33029105
[TBL] [Abstract][Full Text] [Related]
9. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes.
Loganathan S; Kuppusamy M; Wankhar W; Gurugubelli KR; Mahadevappa VH; Lepcha L; Choudhary AK
Respir Physiol Neurobiol; 2021 Jan; 283():103548. PubMed ID: 32956843
[TBL] [Abstract][Full Text] [Related]
11. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
13. Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS.
Perlin DS; Zafir-Lavie I; Roadcap L; Raines S; Ware CF; Neil GA
mSphere; 2020 Aug; 5(4):. PubMed ID: 32817460
[TBL] [Abstract][Full Text] [Related]
14. Optimal therapeutic strategy using extracorporeal membrane oxygenation in patients with COVID-19.
Imamura T; Nikhil N
J Card Surg; 2020 Oct; 35(10):2872-2873. PubMed ID: 33043665
[No Abstract] [Full Text] [Related]
15. Establishing a Unified COVID-19 "Immunome": Integrating Coronavirus Pathogenesis and Host Immunopathology.
Wauters E; Thevissen K; Wouters C; Bosisio FM; De Smet F; Gunst J; Humblet-Baron S; Lambrechts D; Liston A; Matthys P; Neyts J; Proost P; Weynand B; Wauters J; Tejpar S; Garg AD
Front Immunol; 2020; 11():1642. PubMed ID: 32719686
[No Abstract] [Full Text] [Related]
16. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.
Copaescu A; Smibert O; Gibson A; Phillips EJ; Trubiano JA
J Allergy Clin Immunol; 2020 Sep; 146(3):518-534.e1. PubMed ID: 32896310
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
Qin H; Zhao A
Protein Cell; 2020 Oct; 11(10):707-722. PubMed ID: 32519302
[TBL] [Abstract][Full Text] [Related]
18. Immune-Mediated Coagulopathy in COVID-19 Infection.
Vadasz Z; Brenner B; Toubi E
Semin Thromb Hemost; 2020 Oct; 46(7):838-840. PubMed ID: 32877959
[No Abstract] [Full Text] [Related]
19. IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection.
Gadotti AC; de Castro Deus M; Telles JP; Wind R; Goes M; Garcia Charello Ossoski R; de Padua AM; de Noronha L; Moreno-Amaral A; Baena CP; Tuon FF
Virus Res; 2020 Nov; 289():198171. PubMed ID: 32979474
[TBL] [Abstract][Full Text] [Related]
20. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
